Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
Other Sizes |
|
Spliceostatin A is a novel and potent splicing inhibitor targeting sf3b. It is a methylated derivative of FR-901464 that inhibits pre-mRNA splicing.
ln Vitro |
In CLL cells, spliceostatin A (2.5–20 nM; 0–24 h) causes caspase stress in a dose- and time-dependent manner [1]. Following treatment with IL4/CD40L (10 ng/mL, 300 ng/mL; 6 h), spliceostatin A (10 nM, 20 nM; 24 h) exhibits a favorable interaction with ABT-199 or ABT-263, increasing the phosphorylation of CLL cells and decreasing the phosphorylation levels of associated proteins [1]. With IC50 values of 12.1 nM and 61.7 nM, respectively, spliceostatin A suppresses normal B (CD19+) and T (CD3+) activity [1].
|
---|---|
Cell Assay |
Apoptosis analysis[1]
Cell Types: CLL Cell Tested Concentrations: 0, 2.5 nM, 5 nM, 10 nM and 20 nM Incubation Duration: 0, 6 hrs (hours), 12 hrs (hours) and 24 hrs (hours) Experimental Results: Increased apoptosis. Western Blot Analysis[1] Cell Types: CLL Cell Tested Concentrations: 10 nM and 20 nM Incubation Duration: 24 hrs (hours); 10 ng/mL IL4 and/or 300 ng/mL CD40L Results after 6 hrs (hours): PARP, phosphorylated STAT6 (pSTAT6 ), phosphorylated IκBα (pIκBα), Mcl-1L, Bcl-xL, Bcl-2 and Bcl-2 levels were diminished in HSC70. |
References |
[1]. Larrayoz M, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 2016 Feb;30(2):351-60.
[2]. Kaida D, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007 Sep;3(9):576-83. [3]. Roybal GA, et al. Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res. 2010 Oct;38(19):6664-72. |
Molecular Formula |
C28H43NO8
|
---|---|
Molecular Weight |
521.643
|
CAS # |
391611-36-2
|
SMILES |
C/C(/C=C/[C@@H]1[C@@H](O)[C@]2(CO2)C[C@@](OC)(O1)C)=C\C[C@H]3[C@H](C[C@@H](NC(/C=C\[C@@H](OC(C)=O)C)=O)[C@H](O3)C)C
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9170 mL | 9.5852 mL | 19.1703 mL | |
5 mM | 0.3834 mL | 1.9170 mL | 3.8341 mL | |
10 mM | 0.1917 mL | 0.9585 mL | 1.9170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.